Patents by Inventor Paula A. Giesa

Paula A. Giesa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cell culture of hepatitis A virus
    Patent number: 5766603
    Abstract: Hepatitis A virus is attenuated in virulence by in vitro passage in susceptible cell cultures, without prior passage in a subhuman primate. This process results in a live, attenuated hepatitis A virus vaccine suitable for human disease prevention.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: June 16, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Paula A. Giesa, Philip J. Provost, Maurice R. Hilleman
  • Cell culture of hepatitis A virus
    Patent number: 5514376
    Abstract: Hepatitis A virus is attenuated in virulence by in vitro passage in susceptible cell cultures, without prior passage in a subhuman primate. This process results in a live, attenuated hepatitis A virus vaccine suitable for human disease prevention.
    Type: Grant
    Filed: February 10, 1993
    Date of Patent: May 7, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Paula A. Giesa, Philip J. Provost, Maurice R. Hilleman
  • Attenuated hepatitis A virus
    Patent number: 5021348
    Abstract: Hepatitis A virus is attenuated by propagation in cell culture in vitro by direct inoculation of the cell cultures with a human clinical specimen containing the virus.
    Type: Grant
    Filed: May 14, 1984
    Date of Patent: June 4, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Paula A. Giesa, Maurice R. Hilleman, Philip J. Provost
  • Growth of hepatitus A virus in vero cells
    Patent number: 4783407
    Abstract: Hepatitus A virus is grown in Vero cells after passage in in vitro cell culture. Virus replication and continued passage in Vero cells requires extended incubation times, up to about four weeks, for early passages and incubation temperatures no higher than about 32.degree. C. Continued passage results in a significant decrease in incubation time and an increase in virus yield. Cultivation of hepatitus A virus in Vero cells meets the development requirements for an inactivated human vaccine.
    Type: Grant
    Filed: September 30, 1985
    Date of Patent: November 8, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Philip J. Provost, Paula A. Giesa, William J. McAleer